These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 20663870)

  • 21. Novel indoloquinoline derivative, IQDMA, inhibits STAT5 signaling associated with apoptosis in K562 cells.
    Yang SH; Chien CM; Su JC; Chen YL; Chang LS; Lin SR
    J Biochem Mol Toxicol; 2008; 22(6):396-404. PubMed ID: 19111001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipocalin-2 is associated with modulation of disease phenotype in a patient with concurrent JAK2-V617F and BCR-ABL mutation.
    Nadarajan VS; Ang CH; Bee PC
    Eur J Haematol; 2012 Feb; 88(2):175-8. PubMed ID: 21950422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FOXO target gene CTDSP2 regulates cell cycle progression through Ras and p21(Cip1/Waf1).
    Kloet DE; Polderman PE; Eijkelenboom A; Smits LM; van Triest MH; van den Berg MC; Groot Koerkamp MJ; van Leenen D; Lijnzaad P; Holstege FC; Burgering BM
    Biochem J; 2015 Jul; 469(2):289-98. PubMed ID: 25990325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
    Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells.
    Coppo P; Flamant S; De Mas V; Jarrier P; Guillier M; Bonnet ML; Lacout C; Guilhot F; Vainchenker W; Turhan AG
    Br J Haematol; 2006 Jul; 134(2):171-9. PubMed ID: 16846476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
    Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
    J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Down regulation of Chk1 by p53 plays a role in synergistic induction of apoptosis by chemotherapeutics and inhibitors for Jak2 or BCR/ABL in hematopoietic cells.
    Umezawa Y; Kurosu T; Akiyama H; Wu N; Nogami A; Nagao T; Miura O
    Oncotarget; 2016 Jul; 7(28):44448-44461. PubMed ID: 27286446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
    Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
    Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
    Tong H; Ren Y; Zhang F; Jin J
    Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The incidence of co-existing BCR-ABL1 and JAK2 V617F rearrangements: implications for molecular diagnostics.
    McCarron SL; Haslam K; Crampe M; Langabeer SE
    Lab Hematol; 2012 Dec; 18(4):20-1. PubMed ID: 23253862
    [No Abstract]   [Full Text] [Related]  

  • 31. Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.
    Laubach JP; Fu P; Jiang X; Salter KH; Potti A; Arcasoy MO
    Exp Hematol; 2009 Dec; 37(12):1411-22. PubMed ID: 19815050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
    Masykura N; Habibah U; Selasih SF; Gani S; Irawan C; Somoastro S; Handoyo Utomo AR
    Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):220-227. PubMed ID: 30772299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
    Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
    Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.
    Bee PC; Gan GG; Nadarajan VS; Latiff NA; Menaka N
    Int J Hematol; 2010 Jan; 91(1):136-9. PubMed ID: 20047097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction of Raf kinase inhibitor protein expression by Bcr-Abl contributes to chronic myelogenous leukemia proliferation.
    Takemura T; Nakamura S; Yokota D; Hirano I; Ono T; Shigeno K; Fujisawa S; Ohnishi K
    J Biol Chem; 2010 Feb; 285(9):6585-94. PubMed ID: 20028985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.
    Woessner DW; Lim CS
    Mol Pharm; 2013 Jan; 10(1):270-7. PubMed ID: 23211037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation.
    Barnes K; McIntosh E; Whetton AD; Daley GQ; Bentley J; Baldwin SA
    Oncogene; 2005 May; 24(20):3257-67. PubMed ID: 15735728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.
    Walz C; Ahmed W; Lazarides K; Betancur M; Patel N; Hennighausen L; Zaleskas VM; Van Etten RA
    Blood; 2012 Apr; 119(15):3550-60. PubMed ID: 22234689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.
    Ichim CV
    Stem Cells Transl Med; 2014 Apr; 3(4):405-15. PubMed ID: 24598782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
    Weisberg E; Banerji L; Wright RD; Barrett R; Ray A; Moreno D; Catley L; Jiang J; Hall-Meyers E; Sauveur-Michel M; Stone R; Galinsky I; Fox E; Kung AL; Griffin JD
    Blood; 2008 Apr; 111(7):3723-34. PubMed ID: 18184863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.